What is neoadjuvant treatment in breast cancer care?
Neoadjuvant treatment means receiving therapy such as chemotherapy or hormone therapy before breast cancer surgery. The goal is to shrink or control the tumour and prepare for the safest and most effective operation.
Neoadjuvant therapy differs from adjuvant treatment, which is given after surgery. Doctors may recommend neoadjuvant treatment for several reasons, including making breast conservation possible, checking how tumours respond to certain drugs, or addressing cancers found in lymph nodes at the outset.
Common approaches include neoadjuvant chemotherapy, hormone therapy, or targeted therapy, all guided by NICE guidelines and multidisciplinary team input, often referred to as MDT planning in NHS centres. The idea is not to “delay” surgery, but to organise treatment in a sequence that gives the best chance for successful surgery and long-term control. This plan is carefully considered and monitored by the oncology and breast surgery team.
Pro Tip: When considering neoadjuvant therapy, bring a written list of questions to your consultant to help focus the discussion on your main concerns.
Why consider chemo before surgery?
Doctors sometimes offer chemotherapy before surgery to achieve specific treatment goals in breast cancer. This approach is most often used in these situations:
- Shrinking tumours to allow for breast-conserving surgery (such as lumpectomy instead of mastectomy).
- Assessing how tumours respond to particular drugs, which can guide ongoing treatment decisions.
- Reducing the extent or challenge of surgery required, for instance by treating cancer found in lymph nodes at diagnosis.
- Addressing situations where immediate surgery may be riskier, or where a tumour’s biology means an early response to medication could improve the overall outcome.
Some patients worry that starting with medication instead of surgery means the cancer is “left untreated” or can worsen, but clinical monitoring continues throughout neoadjuvant therapy. Imaging and clinic reviews help ensure the plan stays on track and that surgery remains timely.
How neoadjuvant therapy can change surgical options
Receiving treatment before surgery can significantly influence the type of operation you are offered. For example, a large tumour that initially requires mastectomy may become small enough for a lumpectomy after neoadjuvant chemotherapy. Tumour shrinkage may also increase the likelihood of clear margins, which reduces the chance of a second operation for more tissue removal.
The response to neoadjuvant therapy helps plan the primary operation, but also possible reconstruction options. Some patients find that immediate reconstruction becomes possible after a good treatment response, while others may be advised to delay reconstruction if there is uncertainty about how much tissue will need to be removed. The surgical team will also consider long-term outcomes, symmetry, and oncoplastic principles to ensure the operation plan matches your needs and preferences.
Breast-conserving surgery, mastectomy, and different timings for reconstruction are all reviewed in light of the tumour’s response to initial treatment. The MDT, including breast surgeons, radiologists, and oncologists, revises the surgical strategy as new information becomes available during therapy.
Book an Expert Consultation
Who is (and isn’t) suitable for neoadjuvant treatment?
Neoadjuvant therapy is not routine for every breast cancer patient. Several factors help doctors decide if this approach is appropriate.
- Tumour type: Some subtypes, such as triple-negative breast cancer or HER2-positive cancers, are more likely to respond well to treatment before surgery.
- Stage of cancer: Larger tumours or those involving lymph nodes are common reasons for considering the approach.
- Tumour biology: Hormone receptor status, genetic factors, and molecular tests influence responses and treatment plans.
- Patient health: Other medical conditions and overall fitness can shape recommendations.
There are some situations where neoadjuvant treatment may not be suggested, such as small, hormone-sensitive tumours with low risk of spread, or where the tumour is unlikely to respond well to the drugs used. Genetic risk and family history may also play a part in decision making, usually discussed in a specialist breast clinic.
Pro Tip: If you experience side effects during treatment, report them quickly to your team as early intervention can make a significant difference.
What to expect during neoadjuvant treatment and surgery planning
The pathway from diagnosis to surgery with neoadjuvant therapy involves clear stages.
- Assessment: Patients usually have imaging (such as mammogram, ultrasound, or MRI) and a biopsy to confirm the cancer type and guide planning.
- MDT discussion: The cancer is reviewed in a multidisciplinary meeting, often called the MDT, where surgeons, oncologists, radiologists, and pathologists agree the recommended plan.
- Starting treatment: Neoadjuvant therapy begins, with regular monitoring through clinic visits and repeat scans to track changes in the tumour.
- Review: After treatment cycles finish, a new assessment checks how well the tumour has responded. This may include further imaging or sometimes a repeat biopsy.
- Surgical planning: The surgical team, led by a consultant breast surgeon, discusses updated operation options that reflect changes following treatment. This includes potential timing for any reconstructive surgery.
- Operation: Surgery takes place, with the aim to remove the cancer safely and, where feasible, achieve the most suitable cosmetic and clinical outcome.
Throughout, consultant-led care at centres such as the One Stop Breast Clinic ensures assessments and next steps are managed in a coordinated way, helping to reduce uncertainty.
Explore Reconstruction Choices
Risks, trade-offs, and common misconceptions
Neoadjuvant therapy offers important benefits in selected cases, but it is important to be aware of both the risks and common misunderstandings.
Risks and Limitations:
- Side effects can include tiredness, nausea, hair loss, or infection risk, which are monitored and managed by the care team.
- Not all tumours shrink enough for less extensive surgery. Sometimes, despite initial hopes, the original surgical plan still stands.
- There is a limit to what drugs can achieve before surgery. Complete disappearance of a tumour on scans does not always mean all cancer cells have gone, so surgery remains necessary.
Trade-Offs:
- Immediate reconstruction may not always be possible if the treatment response is incomplete, requiring revisions to the reconstruction schedule.
- There may be longer treatment timelines with multiple appointments before surgery.
Misconceptions:
- Myth: “Starting chemo first lets me avoid surgery altogether.” Fact: Surgery is still important for nearly all breast cancer patients, even after a strong treatment response.
- Myth: “Waiting for surgery is harmful.” Fact: Ongoing monitoring, regular imaging, and MDT supervision keep treatment safely on track.
Patients are urged to report symptoms such as redness, fevers, or sudden swelling, as these may indicate an infection or unexpected complication needing prompt medical attention.
Questions to ask your consultant and next steps
When discussing neoadjuvant therapy and surgery planning, consider the following questions:
- What type of breast cancer do I have, and why is neoadjuvant therapy being suggested?
- How will treatment before surgery change my options for breast-conserving surgery or mastectomy?
- What side effects might I experience, and how can I prepare for them?
- Will I still need surgery after preoperative treatment?
- What are the options for reconstruction, and when can they be discussed safely?
- How will you monitor my response during treatment?
- Who will I see for follow-up, and how do I get in touch if I am unwell during therapy?
If you have concerns or feel unsure about the treatment plan, it is sensible to request a second opinion or ask for more information at your next appointment. London-based consultant breast and oncoplastic clinics are experienced in guiding patients through these decisions.
Calm, clear communication remains at the centre of good care during neoadjuvant treatment. Book a Consultation or request a Second Opinion if you would like a further review of your options or pathway.
Located on Harley Street, D B Ghosh Breast Surgeon Specialist in Cancer and Cosmetic Surgery, London delivers high-level specialist care across breast diagnosis, cancer treatment, reconstruction, and cosmetic surgery. Enquiries can be made by calling 020 7205 2281 or visiting Rapid Diagnostic Centre, 146 Harley St, London W1G 7LD.
